Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Selective anticancer chimeric peptide comprising an EGF receptor-binding peptide and a cytotoxic peptide

Selective anticancer chimeric peptide comprising an EGF receptor-binding peptide and a cytotoxic peptide

US Patent 8436137 · Granted May 7, 2013

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods of treating and preventing inflammatory bowel disease involving IL-13 an2015
Selective anticancer chimeric peptides which bind transferrin receptor2015
Selective anticancer chimeric peptides which bind transferrin receptor2015
Selective anticancer chimeric peptides which bind transferrin receptor2015
Selective anticancer chimeric peptides which bind transferrin receptor2015
Selective anticancer chimeric peptides which bind transferrin receptor2015
Selective anticancer chimeric peptides which bind transferrin receptor2015
Selective anticancer chimeric peptides which bind neuropilin receptor2015
Selective anticancer chimeric peptides which bind neuropilin receptor2015
Selective anticancer chimeric peptides which bind neuropilin receptor2015
Selective anticancer chimeric peptides which bind neuropilin receptor2015
Selective anticancer chimeric peptides which bind neuropilin receptor2015